{
    "ticker": "LHDXQ",
    "name": "Lucid Diagnostics, Inc.",
    "description": "Lucid Diagnostics, Inc. is an innovative medical technology company dedicated to the development and commercialization of diagnostic and therapeutic products for the detection and management of cancer. Founded in 2018, Lucid has pioneered its flagship product, the EsoGuard test, which utilizes advanced technology to analyze cells collected from the esophagus. This non-invasive test aims to identify patients at risk for esophageal cancer, particularly in individuals with Barrett's esophagus, a precancerous condition. Lucid\u2019s mission is to enhance patient outcomes through earlier detection and intervention, thereby improving the quality of life for those at risk. The company leverages cutting-edge research and development to expand its product offerings and continuously improve its diagnostic capabilities. Lucid is committed to establishing itself as a leader in the diagnostics field, focusing on patient-centric solutions that empower healthcare providers and patients alike. With a robust pipeline of products and a focus on strategic partnerships, Lucid Diagnostics is well-positioned to make significant contributions to cancer care and management.",
    "industry": [
        "Medical Diagnostics",
        "Healthcare"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2018",
    "website": "https://www.luciddiagnostics.com",
    "ceo": "David L. Beech",
    "social_media": {
        "twitter": "https://twitter.com/LucidDx",
        "linkedin": "https://www.linkedin.com/company/lucid-diagnostics/",
        "facebook": "https://www.facebook.com/LucidDiagnostics"
    },
    "investor_relations": "https://investors.luciddiagnostics.com",
    "key_executives": [
        {
            "name": "David L. Beech",
            "position": "CEO"
        },
        {
            "name": "Michael S. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Tests",
            "products": [
                "EsoGuard"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lucid Diagnostics, Inc. | Innovative Cancer Diagnostic Solutions",
        "meta_description": "Explore Lucid Diagnostics, Inc., a leader in cancer diagnostics focusing on early detection and management. Learn about EsoGuard and its impact on healthcare.",
        "keywords": [
            "Lucid Diagnostics",
            "Cancer Diagnostics",
            "EsoGuard",
            "Esophageal Cancer",
            "Medical Technology"
        ]
    },
    "faq": [
        {
            "question": "What is Lucid Diagnostics known for?",
            "answer": "Lucid Diagnostics is known for its innovative diagnostic test, EsoGuard, which detects esophageal cancer risk."
        },
        {
            "question": "Who is the CEO of Lucid Diagnostics?",
            "answer": "David L. Beech is the CEO of Lucid Diagnostics, Inc."
        },
        {
            "question": "Where is Lucid Diagnostics headquartered?",
            "answer": "Lucid Diagnostics is headquartered in New York, New York, USA."
        },
        {
            "question": "What products does Lucid Diagnostics offer?",
            "answer": "Lucid Diagnostics offers the EsoGuard diagnostic test for the detection of esophageal cancer risk."
        },
        {
            "question": "When was Lucid Diagnostics founded?",
            "answer": "Lucid Diagnostics was founded in 2018."
        }
    ],
    "competitors": [
        "EXAS",
        "MDGL",
        "RGEN"
    ],
    "related_stocks": [
        "GILD",
        "AMGN",
        "JNJ",
        "PFE"
    ]
}